NEXTGEN-TIL (Vall d'Hebron Institute of Oncology)

N/A

Report date: 2022/02/22 13:41:14

Base Information

Drug NameNEXTGEN-TIL (Vall d'Hebron Institute of Oncology)

Drug Alias NameTumor-infiltrating Lymphocyte Adoptive Cell Therapy (Vall D'Hebron Institute Of Oncology)

ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Tumor Infiltrating Lymphocytes

Mechanisms of ActionT lymphocyte replacements

TargetsNot applicable

Therapy Area/IndicationsSolid tumoursCarcinoma

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritorySpain

CombinationsNo

Global Highest StatusPhase 1 Clinical

Highest Status in ChinaN/A

Originator CompaniesVall D'Hebron Institute Of Oncology

China Registration ClassN/A

Develop Information

Active CompaniesVall D'Hebron Institute Of Oncology

Inactive CompaniesN/A

Active IndicationsSolid tumoursCarcinoma

Inactive IndicationsN/A

Other Information

ATC CodeN/A